drugset
drugset / Trial / NCT07298824

Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia

NCT07298824 ↗

Phase 2 Recruiting 164 enrolled Second Affiliated Hospital of Nanchang University
RandomizedParallel-groupDouble-blindPrevention

Summary

To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).

Timeline

Start
2025-10-01
Primary completion
2027-07-01
Completion
2027-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator MR-61 Other / unclassified — Oral

Indications

myopia